639 related articles for article (PubMed ID: 33995657)
41. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
[TBL] [Abstract][Full Text] [Related]
42. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
43. Regulation of the sodium/iodide symporter by retinoids--a review.
Schmutzler C
Exp Clin Endocrinol Diabetes; 2001; 109(1):41-4. PubMed ID: 11573138
[TBL] [Abstract][Full Text] [Related]
44. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.
Sabra MM; Dominguez JM; Grewal RK; Larson SM; Ghossein RA; Tuttle RM; Fagin JA
J Clin Endocrinol Metab; 2013 May; 98(5):E829-36. PubMed ID: 23533233
[TBL] [Abstract][Full Text] [Related]
46. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.
Feng F; Yehia L; Ni Y; Chang YS; Jhiang SM; Eng C
Cancer Res; 2018 Nov; 78(21):6121-6133. PubMed ID: 30217930
[TBL] [Abstract][Full Text] [Related]
47. HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells.
Chai W; Ye F; Zeng L; Li Y; Yang L
J Exp Clin Cancer Res; 2019 Jul; 38(1):325. PubMed ID: 31331356
[TBL] [Abstract][Full Text] [Related]
48. TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells.
Faria M; Domingues R; Paixão F; Bugalho MJ; Matos P; Silva AL
PLoS One; 2020; 15(2):e0228794. PubMed ID: 32049985
[TBL] [Abstract][Full Text] [Related]
49. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.
Kogai T; Brent GA
Pharmacol Ther; 2012 Sep; 135(3):355-70. PubMed ID: 22750642
[TBL] [Abstract][Full Text] [Related]
50. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
51. Antagonistic effects of RAC1 and tumor-related RAC1b on NIS expression in thyroid.
Faria M; Félix D; Domingues R; Bugalho MJ; Matos P; Silva AL
J Mol Endocrinol; 2019 Nov; 63(4):309-320. PubMed ID: 31590142
[TBL] [Abstract][Full Text] [Related]
52. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
53. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
[TBL] [Abstract][Full Text] [Related]
54. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.
Plantinga TS; Tesselaar MH; Morreau H; Corssmit EP; Willemsen BK; Kusters B; van Engen-van Grunsven AC; Smit JW; Netea-Maier RT
Autophagy; 2016 Jul; 12(7):1195-205. PubMed ID: 27105307
[TBL] [Abstract][Full Text] [Related]
55. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
Mishra A; Pal L; Mishra SK
World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
[TBL] [Abstract][Full Text] [Related]
56. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
57. Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.
Tesselaar MH; Smit JW; Nagarajah J; Netea-Maier RT; Plantinga TS
J Mol Endocrinol; 2017 Nov; 59(4):R141-R154. PubMed ID: 28931558
[TBL] [Abstract][Full Text] [Related]
58. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
Ingeson-Carlsson C; Nilsson M
Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
[TBL] [Abstract][Full Text] [Related]
59. Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents.
Patel A; Jhiang S; Dogra S; Terrell R; Powers PA; Fenton C; Dinauer CA; Tuttle RM; Francis GL
Pediatr Res; 2002 Nov; 52(5):737-44. PubMed ID: 12409522
[TBL] [Abstract][Full Text] [Related]
60. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]